Aura Biosciences, Inc. (NASDAQ:AURA)
| Market Cap | $714.99M+24.9% |
| Revenue (ttm) | $0 |
| Net Income | -$136.95M-28.6% |
| EPS | -$1.67+13.9% |
| Shares Out | 104.07M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 791,134 |
| Open | $6.81 |
| Previous Close | $6.98 |
| Day's Range | $6.79 - $6.98 |
| 52-Week Range | $4.73 - $9.54 |
| Beta | 0.44 |
| Analysts | Buy |
| Price Target | $16.50(+140.17%) |
| Earnings Date | Mar 29, 2027 |
About AURA
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 29, 2027Earnings report
$AURA stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in AURA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by AURA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
AURA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New AURA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to AURA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in AURA
| VTIVanguard Morningstar Total Stock Market ETF | $13.54M |
| IWMiShares Russell 2000 ETF | $10.64M |
| XBIState Street SPDR S&P Biotech ETF | $6.71M |
| VXFVanguard Extended Market ETF | $6.61M |
| IWOiShares Russell 2000 Growth ETF | $3.54M |
| IBBiShares Biotechnology ETF | $3.54M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from AURA’s recent data — informational, not investment advice
What’s Behind the Score
News check: Partnership expansion for lead oncology program, analyst upgrades citing growth potential, and Q3 results reporting support bullish outlook with concrete business developments.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| BBC | Virtus Biotech Clinical Trials ETF | 0.88% |
| EVNT | AltShares Event-Driven ETF | 0.61% |
| WCEO | Hypatia Women CEO ETF | 0.22% |
| IWC | iShares Micro-Cap ETF | 0.11% |
| FSEG | Fidelity Enhanced Small Cap Growth ETF | 0.08% |
| XBI | State Street SPDR S&P Biotech ETF | 0.07% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 0.05% |
| FESM | Fidelity Enhanced Small Cap ETF | 0.04% |
| IBB | iShares Biotechnology ETF | 0.03% |
| BIB | ProShares Ultra Nasdaq Biotechnology | 0.03% |
| FSEV | Fidelity Enhanced Small Cap Value ETF | 0.02% |
| PWS | Pacer WealthShield ETF | 0.01% |
Weight is the stock’s share of each fund’s holdings.
